The 3 Biggest Insider Buys of May 2026:
$KLRA, $ODTX and $ARTV

Form 4 and the Signal That Actually Matters

Most retail investors have heard some version of the insider buying narrative: when executives purchase shares in their own company, it signals confidence. What most investors do not do is distinguish between the different types of insider transactions reported on SEC Form 4, and that distinction is where the real signal lives.

Form 4 is filed by corporate insiders — officers, directors, and shareholders owning more than 10% of a company — whenever they buy or sell securities. The form uses transaction type codes. Code S is a sale. Code A is a grant of securities. Code M is the exercise of a derivative (typically options). Code F is a tax-related withholding. None of these are what you should be looking at.

Code P is a purchase — an open-market or concurrent-placement transaction where an insider uses their own money to buy shares at current market prices. Insiders sell for a hundred reasons: diversification, tax planning, estate planning, funding a house purchase, pre-planned 10b5-1 schedules set up months in advance. Insiders usually buy for a much narrower set of reasons than they sell: they believe the risk/reward at the purchase price is attractive. That does not make the signal infallible, but Code P purchases are generally more informative than grants, option exercises or tax-related transactions.

The analysis below uses Code P Form 4 data extracted from OpenInsider, covering the period April 16 to May 18, 2026. From the full universe of U.S.-listed small and mid-cap companies, three names stand out for the sheer magnitude of dollar-value insider accumulation: Kailera Therapeutics (KLRA) with approximately $167 million in clustered buying at and shortly after its April IPO; Odyssey Therapeutics (ODTX) with approximately $75 million from four distinct insider buyers at its May IPO; and Artiva Biotherapeutics (ARTV) with approximately $75 million deployed by Ra Capital Management in a May 2026 follow-on offering.

A methodological note is essential here: all three of these transactions occurred in connection with recent equity offerings — an IPO for KLRA and ODTX, and a follow-on for ARTV. This context does not diminish the signal. Participating in a concurrent private placement at an IPO price, or deploying $75 million into a follow-on offering, is a discretionary, convictional act by a sophisticated institutional insider. These are not passive index allocations. These are deliberate, large-scale bets by people who know these businesses better than anyone in the public market.

The Three Names — Aggregate Insider Buying Summary

Source: OpenInsider / SEC Form 4. Prices from Finviz Elite API, May 18 2026.

Company Overview: The Obesity Drug Race and the Case for KLRA

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of injectable and oral GLP-1-based therapies for clinical obesity and chronic weight management. The company went public on Nasdaq on April 16, 2026, in one of the most significant biotech IPOs of the year — raising approximately $718.8 million in total proceeds after the greenshoe was exercised, against an original target of $500 million that was first upsized to $625 million and ultimately to the final amount. The sheer scale of the raise is itself a signal: investors — institutional and insider alike — competed aggressively to own a piece of this story at $16 per share.

The obesity and GLP-1 drug market is the single most discussed opportunity in biopharma. Eli Lilly’s tirzepatide (Mounjaro/Zepbound), which acts on both GLP-1 and GIP receptors, generated over $13 billion in sales in 2025. Novo Nordisk’s semaglutide franchise (Ozempic/Wegovy) generated over $24 billion. Both companies have market capitalizations measured in the hundreds of billions of dollars. The market signal is unambiguous: effective obesity therapeutics with manageable side-effect profiles are among the most commercially valuable drugs ever developed. The question for investors in Kailera is whether the company’s lead molecule — ribupatide — can compete.

Lead Program: Ribupatide — The Data Behind the $719 Million Bet

Ribupatide is a dual GLP-1/GIP receptor agonist — the same mechanism class as tirzepatide — that Kailera in-licensed from Hengrui Pharmaceuticals, China’s largest pharmaceutical company. The critical data point supporting the IPO valuation comes from a 48-week Phase 3 trial conducted by Hengrui in China: patients receiving the highest dose (6 mg once-weekly injection) achieved a mean weight reduction of 17.7%, compared with 1.4% for placebo. This efficacy profile is competitive with tirzepatide’s pivotal SURMOUNT-1 data (20.9% mean weight loss at the highest dose) and substantially better than liraglutide or older GLP-1 agents.

Kailera’s global development plan involves three large Phase 3 trials — using a reformulated version of ribupatide developed for global markets — with the capital from the IPO deployed specifically to fund these programs. The $625 million core IPO proceed allocation is earmarked for the global Phase 3 trials of injectable ribupatide. An additional $150 million is designated for an oral formulation of ribupatide (KAI-9531), with the Phase 3 program expected to initiate in H1 2027. A third program — KAI-7535, a separate oral GLP-1 candidate — has Phase 2 data expected in 2027.

The pipeline therefore has a layered risk profile: the injectable ribupatide program, with Phase 3 already running and based on compelling Phase 3 data from Hengrui, is the near-term de-risked core. The oral programs represent the upside scenario — if oral ribupatide can achieve meaningful weight loss with acceptable tolerability in a once-daily pill format, the commercial addressable market expands dramatically beyond the injectable-willing patient population.

Why Bain Capital Bought $159 Million in the First Week After the IPO

The Form 4 data tells a specific story. Bain Capital Investors LLC — one of the most accomplished healthcare private equity firms in the world, with a multi-decade track record of building pharmaceutical companies from venture stage to commercial scale — filed a Form 4 on April 20, 2026, four days after the Kailera IPO. Bain bought 8,398,438 shares at $16.00 per share, for a total consideration of $134,375,008. Simultaneously, Bain Capital Life Sciences Investors LLC deployed an additional $25 million, and RTW Investments — a specialist healthcare investment firm that has backed numerous successful biotech IPOs — filed a Form 4 showing $8 million in purchases.

This is a cluster buy by any definition. Three separate sophisticated buyers, all acting within days of the IPO, deploying a combined $167 million at the initial offering price. The message embedded in this Form 4 data is simple: Bain Capital, which presumably had access to all of the ribupatide preclinical and clinical data during the IPO diligence process, concluded that $16 per share was a price they were willing to own at scale. Not as a flip. As a position. The Form 4 buying is conviction buying, not opportunistic micro-rotation.

Catalyst Timeline

Company Overview: Precision Medicine in Inflammatory Bowel Disease

Odyssey Therapeutics is a precision medicine company that went public on the Nasdaq Capital Market in May 2026, raising capital through an initial public offering at $18 per share. The company is built around a focused pipeline in immunology and inflammation, with its most advanced program — OD-001 — targeting a molecular mechanism in inflammatory bowel disease that has attracted significant scientific and commercial attention: RIPK2 scaffolding inhibition.

Ulcerative colitis and Crohn’s disease together affect an estimated 1.6 million people in the United States and 10 million globally. The market for IBD drugs exceeded $20 billion in 2025, dominated by biologics including Humira (adalimumab), Stelara (ustekinumab), and a growing class of JAK inhibitors. Despite this breadth of available therapies, a substantial proportion of IBD patients — particularly those with moderate-to-severe disease — do not achieve or sustain remission on current treatments. This unmet need drives continued investment in next-generation mechanisms, and RIPK2 represents one of the more scientifically differentiated approaches to enter clinical development.

The RIPK2 Mechanism: Why Precision Matters

RIPK2 (Receptor-Interacting Serine/Threonine Kinase 2) is an intracellular protein that plays a critical role in the innate immune signaling pathway downstream of NOD1 and NOD2 — two pattern recognition receptors that are activated when the immune system detects bacterial cell wall components. In patients with certain NOD2 mutations — which are among the strongest genetic risk factors for Crohn’s disease — this pathway becomes dysregulated, driving chronic intestinal inflammation.

Most drugs that target kinases do so by blocking the kinase’s enzymatic activity. Odyssey’s approach with OD-001 is different: it targets the scaffolding function of RIPK2 — the protein’s role in assembling the signaling complex — rather than its kinase activity. This “scaffolding inhibition” approach is designed to achieve pathway specificity that is not possible with classical kinase inhibitors, potentially yielding a cleaner efficacy and safety profile. OD-001 is in Phase 2a development for ulcerative colitis.

The Four-Buyer Cluster: Why Four Distinct Sophisticated Investors Means More Than One

The Form 4 data for ODTX is particularly compelling because of the diversity of the buyer cohort. Four separate entities — TPG (a $220 billion alternative asset management firm), Dimension Capital (a specialist healthcare fund), Li Nan (a director with direct governance visibility into the company’s operations), and SR One Capital Management (GlaxoSmithKline’s former venture capital arm, now independent) — all deployed capital at the IPO price of $18 in the same week. This is not coincidental aggregation. It reflects four independent due diligence processes, four separate investment committee approvals, and four distinct pools of capital all reaching the same conclusion: $18 per share is a price worth owning.

The TPG concurrent private placement of $25 million is particularly noteworthy. TPG LSI Rise Orazio II, L.P. agreed to purchase approximately $25 million in shares at the IPO price simultaneously with the offering — a commitment that was made and locked before the stock began trading. This is a meaningful expression of conviction: paying the same price as the IPO, before the market had time to establish a secondary-trading range. TPG’s life sciences franchise is one of the most respected in the industry, with investments including several FDA-approved drugs and multi-billion-dollar commercial biotechs.

Catalyst Timeline

Company Overview: The NK Cell Therapy Bet on Refractory Autoimmune Disease

Artiva Biotherapeutics is a biotech company developing allogeneic natural killer (NK) cell therapies for autoimmune diseases — a category that has gained extraordinary scientific and commercial momentum following the landmark success of CD19-targeted CAR-T and B-cell depletion strategies in conditions like lupus and myositis. Artiva’s lead program, AlloNK (also referred to as AB-101), is an off-the-shelf, non-genetically modified, cryopreserved NK cell therapy designed to enhance antibody-dependent cellular cytotoxicity (ADCC) when combined with monoclonal antibodies that target B cells — most notably rituximab (anti-CD20).

The scientific premise is elegant: AlloNK is not a standalone drug. It is a cellular augmentation strategy. When administered in combination with rituximab, the AlloNK cells provide a powerful cellular effector function that enhances rituximab’s ability to kill B cells through ADCC. B cells are the pathogenic drivers of multiple autoimmune conditions — including rheumatoid arthritis, lupus, myositis, and Sjögren’s syndrome — and the ability to achieve deep, durable B-cell depletion in refractory patients who have failed conventional B-cell-depleting therapy is the central clinical premise.

The Phase 2a Data That Justified $300 Million

The May 2026 follow-on offering was not initiated in a data vacuum. In April 2026, Artiva presented Phase 2a data from its company-sponsored basket trial in refractory autoimmune diseases. The headline result was striking: 71% of highly refractory rheumatoid arthritis patients in the trial achieved ACR50 — a 50% improvement in RA disease activity — at six months. This efficacy threshold is substantially better than what is typically seen in patients who have already failed multiple biologic therapies (including rituximab itself). The data also showed deep B-cell depletion, meaningful improvements in disease activity scores, and a clean safety profile: no cytokine release syndrome (the most feared serious adverse event in cell therapy), no neurotoxicity, and no AlloNK-related serious adverse events.

This is the data that brought the $300 million investor syndicate to the table. The offering was backed by Caligan Partners, Venrock Healthcare Capital Partners, Adage Capital Partners, Ra Capital Management, Viking Global Investors, Samsara BioCapital, EcoR1 Capital, Blackstone Multi-Asset Investing, and RTW Investments. This is not a collection of generalist investors who happened to click on a prospectus. This is the A-list of specialized healthcare long/short funds deploying capital based on deep clinical diligence — including access to additional patient-level data, investigator conversations, and mechanistic understanding that the public market does not have.

Ra Capital’s $75 Million Bet: Context and Conviction

Ra Capital Management holds a unique position in the biotech investment landscape. Founded by Peter Kolchinsky — a virologist with a doctorate from Harvard — the Boston-based firm manages multi-billion-dollar long/short healthcare portfolios and is widely regarded as one of the most scientifically rigorous institutional investors in the sector. Ra Capital’s due diligence process involves hiring independent scientific experts, running its own preclinical and clinical analyses, and taking concentrated positions only in companies where the fund has developed genuine conviction about the mechanism, the data, and the management team.

Ra Capital’s Form 4 filing showing $74,999,992 in ARTV purchases at the $11.52 follow-on price is therefore not a casual position initiation. It is the result of an extended evaluation process, likely beginning when Artiva was still a private company, that culminated in Ra Capital choosing to be the lead anchor of a $300 million follow-on offering at a price that has since moved below the transaction price. The current stock price of $9.22 means Ra Capital is currently underwater on this position — which, if anything, strengthens the conviction signal. Ra Capital did not sell. They own an even larger position at a higher cost basis and continue to be a reporting insider. The bet remains on.

The Regulatory Pathway: Phase 3 in RA and FDA Fast Track

Artiva has secured FDA Fast Track Designation for AlloNK in refractory rheumatoid arthritis — a regulatory mechanism that provides expedited review, more frequent interactions with FDA during development, and rolling review of the BLA submission. The company has also reached formal agreement with FDA on the Phase 3 registrational trial design. A Phase 3 initiation in 2026 is planned, with a BLA submission targeted for 2029. If AlloNK achieves similar results in the Phase 3 pivotal trial as it did in the Phase 2a basket study — 71% ACR50 in patients who have already failed rituximab and multiple biologics — the commercial opportunity is enormous. There are an estimated 1.3 million RA patients in the U.S. alone, with approximately 35–40% considered refractory to conventional biologic therapy.

Reading the Form 4 Signal: What These Three Transactions Have in Common

The three insider buying events documented above — Bain Capital’s $167 million cluster in KLRA, the four-buyer $75 million IPO-week accumulation in ODTX, and Ra Capital’s $75 million anchor position in ARTV’s follow-on — share a structural characteristic that distinguishes them from most Form 4 filings: they are discretionary, large-scale, Code P transactions by institutional insiders who had access to more information about these companies than any public market participant.

Bain Capital’s healthcare team participated in Kailera’s IPO diligence, reviewed the Hengrui Phase 3 data, assessed the competitive landscape in GLP-1 obesity therapeutics, and concluded that $16 was a price worth owning at $134 million. TPG’s life sciences team concluded that $18 was a price worth locking in for $25 million before ODTX’s stock even began trading on the secondary market. Ra Capital’s scientific team reviewed AlloNK’s Phase 2a patient-level data, assessed the NK cell therapy competitive landscape, and deployed $75 million at $11.52 alongside a $300 million institutional syndicate.

None of these are accidental transactions. None are tax-driven, diversification-driven, or pre-scheduled. They are, by the most reasonable interpretation available, strong directional signals from sophisticated investors who know these businesses well and believe the current prices represent attractive entry points for multi-year investment theses.

What the Form 4 data cannot tell you is that these trades will be right. Bain Capital has backed drugs that failed in Phase 3. TPG has invested in companies that ran out of cash before reaching their pivotal milestones. Ra Capital has positions that went to zero. Insider buying is a probabilistic signal, not a guarantee. The value of monitoring it systematically — and the purpose of analyses like this one — is to shift the informational playing field slightly in favor of the retail investor who is otherwise operating with far less context than the institutional buyer on the other side of the trade.